IL-21 polypeptides and targeted constructs
US12122827B2 · kind B2 · utility
1Cited by
18References
30Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 26, 2023 |
| Grant date | Oct 22, 2024 |
| Priority date | — |
| Expiry date | Apr 26, 2043 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/74
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure provides methods and compositions comprising IL-21 polypeptides, targeted cytokine construct that selectively activates target immune cells (e.g., CD8+ T cells) over other immune cell types. The cytokine of the present disclosure can further comprise mutations that alter its charge distribution to improve its half-life within the blood.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.